Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
Top Page
VistaGen Therapeutics
(NASDAQ:VTGN)
42Neutral
Positive Factors
Clinical Trials
Positive results from the prior PALISADE-2 study increase confidence in ongoing Phase 3 trials for social anxiety disorder.
Financial Position
VistaGen has $97.6M in cash, providing financial runway through FY26.
Negative Factors
Financial Performance
VistaGen reported F3Q25 results with a net loss of ($14.1M).
VistaGen Therapeutics (VTGN) vs. S&P 500 (SPY)
Market Cap
$76.63M
Dividend YieldN/A
Average Volume (3M)181.98K
Price to Earnings (P/E)―
Beta (1Y)1.06
Revenue Growth-33.00%
EPS Growth54.91%
CountryUS
Employees39
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.58
Shares Outstanding28,862,085
10 Day Avg. Volume136,244
30 Day Avg. Volume181,977
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)115.35
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.00Price Target Upside341.18% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
VistaGen Therapeutics Business Overview & Revenue Model
Company DescriptionVistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.
How the Company Makes MoneyVistaGen Therapeutics makes money primarily through the development and commercialization of its drug candidates. The company seeks to generate revenue by bringing its CNS therapies to market, either independently or through strategic partnerships and collaborations with other pharmaceutical companies. These partnerships may involve licensing agreements, co-development deals, and milestone payments, as well as royalties from the sale of successfully approved and marketed drugs. Additionally, VistaGen may receive funding from grants and research collaborations that support its ongoing clinical trials and research initiatives.
VistaGen Therapeutics Financial Statement Overview
Summary
VistaGen Therapeutics faces significant financial challenges with negative growth, profitability, and cash flow metrics. The company is operating with substantial losses and negative cash flows, relying on equity to maintain operations. Despite a strong equity base, the company needs to address profitability and cash generation to ensure sustainability.Income Statement
VistaGen Therapeutics has shown volatile revenue with a significant drop in the TTM period to $698,300 from $1,064,000 in the previous annual report, resulting in a negative revenue growth rate. The company incurs significant losses with a net profit margin of -6769% for TTM, indicating severe profitability issues. EBIT and EBITDA margins are deeply negative, highlighting operating inefficiencies.20
Very Negative
Balance Sheet
The company has a relatively stable equity base with a positive equity ratio of 87.9% for TTM. However, the debt-to-equity ratio is low at 0.02, suggesting minimal leverage but also reflecting limited financial flexibility. Return on equity is negative due to consistent net losses.45
Neutral
Cash Flow
VistaGen Therapeutics shows a negative free cash flow, worsening by approximately 51.6% in the TTM compared to the previous period. The operating cash flow to net income ratio is negative, indicating poor cash conversion. The company relies heavily on financing activities to manage liquidity.30
Negative
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 698.30K | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | Gross Profit |
| 698.30K | 1.06M | -227.00K | 1.11M | 1.09M | 0.00 | EBIT |
| -52.84M | -33.02M | -59.27M | -47.78M | -17.93M | -20.80M | EBITDA |
| -52.38M | -32.45M | -58.74M | -47.05M | -17.44M | -20.65M | Net Income Common Stockholders |
| -47.30M | -29.36M | -59.25M | -47.76M | -17.93M | -20.77M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 88.56M | 119.17M | 16.64M | 68.14M | 103.11M | 1.36M | Total Assets |
| 92.31M | 123.65M | 21.09M | 74.64M | 108.28M | 5.77M | Total Debt |
| 1.71M | 2.12M | 2.72M | 3.04M | 3.72M | 4.09M | Net Debt |
| -73.00M | -117.05M | -13.92M | -65.10M | -99.39M | 2.74M | Total Liabilities |
| 11.19M | 9.37M | 9.01M | 9.93M | 16.30M | 11.50M | Stockholders Equity |
| 81.12M | 114.29M | 12.08M | 64.72M | 91.98M | -5.73M |
| Cash Flow | Free Cash Flow | ||||
| -39.26M | -25.87M | -49.93M | -45.46M | -12.35M | -15.76M | Operating Cash Flow |
| -39.23M | -25.81M | -49.72M | -45.26M | -12.07M | -15.76M | Investing Cash Flow |
| -13.70M | -61.00K | -740.30K | -200.40K | -275.40K | 0.00 | Financing Cash Flow |
| 1.09M | 128.40M | -1.04M | 10.48M | 114.10M | 4.01M |
VistaGen Therapeutics Technical Analysis
Negative
2.72
Price Trends
2.85
Negative
2.82
Negative
3.13
Negative
Market Momentum
-0.05
Negative
48.78
Neutral
75.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTGN, the sentiment is Negative. The current price of 2.72 is below the 20-day moving average (MA) of 2.73, below the 50-day MA of 2.85, and below the 200-day MA of 3.13, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 48.78 is Neutral, neither overbought nor oversold. The STOCH value of 75.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTGN.
VistaGen Therapeutics Risk Analysis
VistaGen Therapeutics disclosed 84 risk factors in its most recent earnings report. VistaGen Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
VistaGen Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $2.87B | 12.64 | 38.89% | ― | 31.85% | ― | |
69 Neutral | $13.96B | ― | -8.58% | ― | 46.62% | 50.50% | |
68 Neutral | $11.05B | 33.69 | 14.16% | ― | 24.81% | 33.67% | |
51 Neutral | $5.83B | ― | -231.63% | ― | 42.53% | -15.29% | |
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
43 Neutral | $454.96M | ― | -63.37% | ― | -52.30% | 27.13% | |
42 Neutral | $76.63M | ― | -46.28% | ― | -33.00% | 54.91% |
* Healthcare Sector Average
Performance Comparison
VTGN
VistaGen Therapeutics
2.72
-1.48
-35.24%
ACAD
ACADIA Pharmaceuticals
17.19
-2.37
-12.12%
NBIX
Neurocrine
107.22
-34.58
-24.39%
ITCI
Intra-Cellular Therapies
131.24
66.03
101.26%
SAGE
SAGE Therapeutics
7.40
-13.21
-64.10%
AXSM
Axsome Therapeutics
119.50
49.60
70.96%
VistaGen Therapeutics Earnings Call Summary
Earnings Call Date: Feb 13, 2025 | % Change Since: -4.56% | Next Earnings Date: Jul 1, 2025
Earnings Call Sentiment Positive
The earnings call reflected a positive sentiment due to the significant progress in clinical trials, a robust and diverse product pipeline, and a strong financial position. However, increased R&D expenses and net loss were notable concerns.Highlights
Progress in Clinical Trials for Fasedienol
Palisade Phase 3 program for fasedienol in treating social anxiety disorder (SAD) is advancing as planned, with Palisade 3 and Palisade 4 expected to report top-line results in 2025. Initiation and enrollment of the first subjects in an exploratory Phase 2 repeat-dose study of fasedienol in SAD were also announced.
Diverse and Innovative Product Pipeline
VistaGen has five clinical-stage intranasal pherine product candidates, all with positive Phase 2 data, and one with Phase 3 positive clinical results. The pipeline's reliance on nose-to-brain neurocircuitry offers a non-systemic and rapid-onset treatment approach.
Strong Financial Position
As of December 31, 2024, VistaGen had $88.6 million in cash, cash equivalents, and marketable securities.
Lowlights
Increased Research and Development Expenses
R&D expenses rose to $11.3 million for the quarter ended December 31, 2024, up from $4.5 million for the same period last year, primarily due to increased expenses related to the Palisade Phase 3 program and IND-enabling programs for other candidates.
Increased Net Loss
Net loss attributable to common stockholders was $14.1 million for the quarter ended December 31, 2024, compared to $6.4 million for the same period last year.
Company Guidance
During VistaGen Therapeutics' third-quarter fiscal year 2025 corporate update call, the company provided guidance on several key metrics and developments. The company reported a significant increase in research and development expenses, totaling $11.3 million for the quarter ended December 31, 2024, compared to $4.5 million in the prior year, attributed to advancements in their Palisade Phase 3 program for fasedienol in social anxiety disorder (SAD) and IND-enabling programs for itruvone and PH80. General and administrative expenses rose slightly to $4.0 million. The net loss for the quarter was $14.1 million, up from $6.4 million the previous year. Financially, VistaGen reported $88.6 million in cash, cash equivalents, and marketable securities as of the end of 2024. The company expressed confidence in delivering top-line results from its ongoing Palisade 3 and 4 Phase 3 trials later in 2025, which, together with Palisade 2, may support a new drug application submission to the FDA. Additionally, VistaGen highlighted progress in its broader pipeline, including the initiation of exploratory studies and plans for further clinical development in other therapeutic areas.VistaGen Therapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
VistaGen Reports Q3 2025 Financial Results and Updates
Positive
Feb 13, 2025
On February 13, 2025, Vistagen reported its financial results for the fiscal year 2025 third quarter and provided a corporate update, highlighting advancements in its clinical-stage pipeline. Notably, the company is progressing with Phase 3 trials for fasedienol in the treatment of social anxiety disorder and announced positive results from a Phase 2A trial of PH284 in cancer cachexia. The increased R&D expenses reflect these advancements. Vistagen is optimistic about the transformative potential of its product candidates to address unmet needs in areas like social anxiety, major depressive disorder, and menopausal hot flashes, with 2025 poised as a pivotal year for data readouts and advancements.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.